entertainment -WSS

entertainment

author：leisure time 2025-08-11 11:44:10 - browse：78

Former MIT and Whitehead Institute star biologist David Sabatini, who lost his positions after he was accused of violating sexual harassment policies in 2021, is resuming his science career, taking a post at a Czech research institute in Prague.

Sabatini, of Cambridge, confirmed in a phone call from Prague that he has accepted a position as a “senior group leader” at the Institute of Organic Chemistry and Biochemistry, known as IOCB Prague. Sabatini said he will be recruiting staff and running a laboratory in the Czech Republic capital to investigate scientific questions in the areas of cell growth and metabolism, similar to his past research in Cambridge.

“I’m very grateful to be given the opportunity to do science again,” said Sabatini, who began working at the institute last month.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： 3 hurdles to bringing medical devices to the U.S. market

explore

WSS

Intellia reports positive results for its CRISPR

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Why are elite athletes different? Take a look at their microbes

The battle over the Brookhaven Landfill on Long Island

Letters to First Opinion on caregivers, digital health, and more

knowledge

entertainment

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Guidelines to prevent youth baseball injuries need more muscle

#NeedHerScience: shining a light on gender disparities in medicine

Moonlake's readout produced a cash windfall. Risks remain

New guidelines on severe brain injury complicate already difficult decisions

Malaria cases in Florida and Texas: Here’s what you need to know

FDA's Pazdur wants cancer trials to range beyond China alone

How one medical school became remarkably diverse

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Wikipedia

With trial win, GSK could get blood cancer drug back on market

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Letters to First Opinion on caregivers, digital health, and more

Death of patient in Alzheimer’s trial raises question of possible risks

Shifting the focus from loneliness to social health

Weight bias in eating disorder treatment complicated by new weight loss drugs

explore

explore

Wikipedia

hotspot